K2 Medical Research The Villages

Lady Lake, Florida 32159

10 studies enrolling now · 17 studies all time

What they study most

Alzheimer Disease, Alzheimer's Disease, Alzheimers Disease, Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Low-back Pain, Chronic Pain, Diabetic Neuropathic Pain, Diabetic Peripheral Neuropathic Pain, Early Preclinical Alzheimer's Disease, Elevated Lp(a), Healthy, Low Back Pain

Studies at this site

• Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) — Recruiting now
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) — Recruiting now
• A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — Recruiting now
• Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies — Recruiting now
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) — Recruiting now
• A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain — Recruiting now
• A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain — Recruiting now
• A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD) — Recruiting now
• A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back Pain — Starting soon
• A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain — Starting soon
• Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease — Running, not enrolling
• AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid — Running, not enrolling
• A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01 — Stopped early
• A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) — Running, not enrolling
• Study of ASN51 in Adults With Early Alzheimer's Disease — Stopped early
• Alzheimer's Plasma Extension — Running, not enrolling
• Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease — Running, not enrolling